NextPharma Asker’s chewable tablets help to maintain bone health

Osteoporosis, a condition that causes bones to become weak and brittle, is common in older adults, but it is not inevitable. Bone health can be improved through sufficient intake of calcium, which is essential for maintaining bone density and strength. Vitamin D3 and Vitamin K2 play an important role as well.

But when people don’t consume enough of these nutrients through diet, they increase their risk of osteoporosis and similar conditions. Nutritional supplements can therefore be a gamechanger for those at risk.

NextPharma Asker develops and manufactures chewable tablets for calcium and vitamin D3 deficiencies, osteoporosis, and prevention of medication-related bone loss. Formulations with Vitamin K2 are available as well. The site is a centre of excellence for chewable tablets and can also do other tablet formulations.

The tablets are affordable, easy to ingest and pleasant to chew. They also come in a variety of strengths and flavours such as lemon, orange, spearmint, and strawberry/watermelon.

All tablets are manufactured with high-quality, pharma-grade materials and processes. Moreover, they are produced according to European Union GMP and Eurasian Economic Union GMP and may be sold as food supplements, over the counter (OTC) or prescription only depending on local regulations.

NextPharma Asker’s high-volume automated manufacturing site is based on lean manufacturing principles and can produce medium to large batches of up to 4 metric tons of chewable tablets. The full range of services includes commercial manufacturing and packaging, product development and improvement, stability testing, scale up, quality control and process validation, as well as regulatory documentation.

The company’s nutritional supplements improve people’s health and quality of life. Calcium is essential for maintaining bone density and strength, and Vitamin D3 enhances calcium absorption, ensuring the body can effectively utilise it.

Vitamin K2 helps to direct calcium to bones and teeth while preventing its accumulation in blood vessels, supporting cardiovascular health. Additionally, Vitamin D3 plays a role in immune system function, contributing to overall health and resilience.

Moreover, the company is committed to sustainability. It uses green energy throughout its production processes and is carbon neutral as of 2025.

The global calcium supplements market is valued at USD 6.19 billion in 2025 and is expected to reach USD 9.22 billion by 2035. Market growth reflects the rising awareness surrounding bone health, particularly among the aging population and women prone to osteoporosis and post-menopausal bone density loss.

NextPharma Asker contributes to this growth, exporting more than 95 per cent of its total production volume. Its tablets are currently sold in 45 countries. In addition, the company can develop new solutions for countries around the world.

NextPharma’s success is based on over 110 years of production experience in Norway.